Cargando…

Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea

Sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors are antidiabetic drugs with associated safety concerns regarding the risk of genital and urinary tract infections. This study assessed the risk of genital and urinary tract infections associated with prescription of SGLT‐2 inhibitors as an add‐on th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hyeri, Choi, Eunmi, Park, Eunjun, Na, Eonji, Chung, Soo Youn, Kim, Bonggi, Han, Soon Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Invited Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929338/ https://www.ncbi.nlm.nih.gov/pubmed/35005849 http://dx.doi.org/10.1002/prp2.910

Ejemplares similares

SGLT2 and cancer
por: Wright, Ernest M.
Publicado: (2020)

Chlamydia trachomatis infection of the male genital tract: what seems to be the trouble?
por: Haidl, Gerhard, et al.
Publicado: (2021)

Risk of aortic aneurysm and aortic dissection with the use of fluoroquinolones in Korea: a nested case–control study
por: Son, Nayeong, et al.
Publicado: (2022)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)

Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes
por: Tanrıverdi, Mustafa, et al.
Publicado: (2023)

SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients
por: Scheen, André J
Publicado: (2020)

Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea
por: Yeon, Bora, et al.
Publicado: (2022)

Recurrent urinary tract infection associated with SGLT‐2 inhibitor in type 2 diabetes mellitus patient: A case report
por: Hazique, Mohammad, et al.
Publicado: (2023)

SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
por: Tamez-Perez, Héctor Eloy, et al.
Publicado: (2017)

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Urinary tract infections (UTIs) or genital tract infections (GTIs)? It's the diagnostics that count
por: Behzadi, Payam, et al.
Publicado: (2019)

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
por: Castellana, Marco, et al.
Publicado: (2019)

Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
por: Liu, Jiali, et al.
Publicado: (2017)

Stop, Listen, and Learn: Using Mixed Methods to Add Value to Clinical Trials*
por: Hunter, Jennifer, et al.
Publicado: (2019)

Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
por: Villar, Miriam Méndez-del, et al.
Publicado: (2017)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia
por: De Nunzio, Cosimo, et al.
Publicado: (2020)

There are no three physiological narrowings in the upper urinary tract: a new concept of the retroperitoneal anatomy around the ureter
por: Kamo, Minobu, et al.
Publicado: (2021)

`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
por: Jeong, Hoon, et al.
Publicado: (2022)

An anatomical pathogenesis of lower urinary tract definitions from the 2002 ICS report symptoms, conditions, syndromes, urodynamics
por: Petros, Peter, et al.
Publicado: (2022)

Trends in add-on medications following metformin monotherapy for type 2 diabetes
por: Swart, Elizabeth CS, et al.
Publicado: (2022)

Urinary tract bleeding from a urethral caruncle mimicking genital tract bleeding
por: Sonoda, Kento, et al.
Publicado: (2019)

Urinary and Genital Tract Obstruction as a Complication of Female Genital Mutilation: Case Report and Literature Review
por: Okwudili, Obi Anselm, et al.
Publicado: (2012)

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control
por: Ridderstråle, Martin, et al.
Publicado: (2013)

What Does SGLT2 Inhibition Add in Managing Hyponatremia Secondary to Syndrome of Inappropriate Antidiuresis (SIAD)?
por: Jalal, Fadzliana Hanum, et al.
Publicado: (2021)

Do lower urinary tract symptoms predict cardiovascular diseases in older men? A systematic review and meta-analysis
por: Bouwman, Iris I., et al.
Publicado: (2015)

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
por: Cakirca, Mustafa, et al.
Publicado: (2014)

Effects of gliclazide add on metformin on serum omentin-1 levels in patients with type 2 diabetes mellitus
por: Al-Gareeb, Ali I., et al.
Publicado: (2016)

The Incidence and Risk Factors of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Using SGLT2 Inhibitors: A Real-World Observational Study
por: Uitrakul, Suriyon, et al.
Publicado: (2022)

Functions of ICC-like cells in the urinary tract and male genital organs
por: Hashitani, Hikaru, et al.
Publicado: (2010)

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Jeon, Ja Young, et al.
Publicado: (2021)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
por: Evans, Marc, et al.
Publicado: (2019)

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2
por: Powell, David R, et al.
Publicado: (2015)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Efficacy and safety of muscarinic antagonists as add-on therapy for male lower urinary tract symptoms
por: Li, Jinhong, et al.
Publicado: (2014)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_85gbokina3dcubm7gkhkit68bt